<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.5d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20130630\txmd_06302013.xfr; Date: 2013/08/06T16:24:41 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:txmd="http://therapeuticsmd.com/20130630">
    <link:schemaRef xlink:href="txmd-20130630.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-08-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_WebsiteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:WebsiteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_WebsiteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:WebsiteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_LongTermIncentiveCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_PernixTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:PernixTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_PernixTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:PernixTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_PernixTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:PernixTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-30to2013-01-31_Debt3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-30</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-31_Debt3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-01to2013-02-28_Debt3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-01</xbrli:startDate>
        <xbrli:endDate>2013-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-01to2013-03-31_Debt3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-01to2013-02-28_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-01</xbrli:startDate>
        <xbrli:endDate>2013-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-02-28_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-28_DebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_Debt1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_Debt2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_Debt4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_Debt4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_Debt5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_Debt6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_Debt1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_Debt1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_Debt2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_Debt2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_DebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_Debt7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-20to2013-03-21_Debt7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-20</xbrli:startDate>
        <xbrli:endDate>2013-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_WarrantMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_WarrantMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_Debt7Member_Warrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt7Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_Debt7Member_Warrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt7Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_Debt7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_Debt4Member_Warrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_Debt4Member_Warrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_Debt4Member_Warrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_Debt4Member_Warrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-29_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-29_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-28to2013-03-29_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-28</xbrli:startDate>
        <xbrli:endDate>2013-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-03-31_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-11-12to2012-11-13_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-11-12</xbrli:startDate>
        <xbrli:endDate>2012-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_PernixTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:PernixTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-24to2013-04-25_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-24</xbrli:startDate>
        <xbrli:endDate>2013-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:SancilioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-05-31_custom_Debt4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_custom_Debt7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-11to2013-04-12_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-11</xbrli:startDate>
        <xbrli:endDate>2013-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_Debt3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:Debt3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:SancilioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-09</xbrli:startDate>
        <xbrli:endDate>2013-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-10_custom_SancilioMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:SancilioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:SancilioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:SancilioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-20</xbrli:startDate>
        <xbrli:endDate>2013-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-21_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-09to2013-05-10_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-09</xbrli:startDate>
        <xbrli:endDate>2013-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-10_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-05to2013-05-06_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-05</xbrli:startDate>
        <xbrli:endDate>2013-05-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-06_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember_custom_Vesting3YearsAnnualMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting3YearsAnnualMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-20</xbrli:startDate>
        <xbrli:endDate>2013-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember_custom_Vesting18monthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting18monthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-20</xbrli:startDate>
        <xbrli:endDate>2013-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember_custom_Vesting3YearsMonthlyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting3YearsMonthlyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-20</xbrli:startDate>
        <xbrli:endDate>2013-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-09to2013-05-10_custom_Vesting4YearsAnnualMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting4YearsAnnualMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-09</xbrli:startDate>
        <xbrli:endDate>2013-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-05to2013-05-06_custom_Vesting12monthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting12monthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-05</xbrli:startDate>
        <xbrli:endDate>2013-05-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_us-gaap_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_custom_CommitteeChairsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CommitteeChairsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-28to2013-03-29_custom_Vesting4YearsAnnualMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting4YearsAnnualMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-28</xbrli:startDate>
        <xbrli:endDate>2013-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-28to2013-03-29_custom_Vesting12monthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting12monthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-28</xbrli:startDate>
        <xbrli:endDate>2013-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-28to2013-03-29_custom_Vesting13monthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting13monthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-28</xbrli:startDate>
        <xbrli:endDate>2013-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-28to2013-03-29_custom_Vesting7monthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting7monthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-28</xbrli:startDate>
        <xbrli:endDate>2013-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-28</xbrli:startDate>
        <xbrli:endDate>2012-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-29_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_Vesting4YearsAnnualMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting4YearsAnnualMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-28</xbrli:startDate>
        <xbrli:endDate>2012-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_Vesting2YearsAnnualMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting2YearsAnnualMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-28</xbrli:startDate>
        <xbrli:endDate>2012-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_Vesting12monthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:Vesting12monthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-28</xbrli:startDate>
        <xbrli:endDate>2012-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_VestingMonthly123112Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">txmd:VestingMonthly123112Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-28</xbrli:startDate>
        <xbrli:endDate>2012-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-15to2012-04-16_us-gaap_EmployeeStockOptionMember_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-15</xbrli:startDate>
        <xbrli:endDate>2012-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-04-16_us-gaap_EmployeeStockOptionMember_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-15to2012-04-16_us-gaap_CallOptionMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-15</xbrli:startDate>
        <xbrli:endDate>2012-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-15to2012-04-16_us-gaap_CallOptionMember_custom_CommitteeChairsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CommitteeChairsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-15</xbrli:startDate>
        <xbrli:endDate>2012-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-04-16_us-gaap_CallOptionMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-04-16_us-gaap_CallOptionMember_custom_CommitteeChairsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CommitteeChairsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPUnit">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>txmd:Unit</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Months">
      <xbrli:measure>txmd:Integer</xbrli:measure>
    </xbrli:unit>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-06-30" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-06-30" unitRef="Shares" decimals="INF">131212706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesIssued>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">72684</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">60600</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">100385</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">42048</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">1102680</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1109276</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="USD" decimals="0">859647</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2013-03-20to2013-03-21_Debt7Member" unitRef="USD" decimals="0">885709</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1102680</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:PrepaidInsurance contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">125266</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">127403</us-gaap:PrepaidInsurance>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">541936</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">432216</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidGuarantyCostsCurrent contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <txmd:PrepaidGuarantyCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2944</txmd:PrepaidGuarantyCostsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">263851</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">114899</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">93853</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">29400</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="AsOf2013-06-30" unitRef="USD" id="Foot-00-0" decimals="0">41359</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="AsOf2012-12-31" unitRef="USD" id="Foot-00-1" decimals="0">41359</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableAmountPerShare contextRef="AsOf2013-06-30" unitRef="USDPShares" decimals="INF">0.40</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.40</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2012-12-31_PernixTherapeuticsMember" unitRef="USD" decimals="0">308000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2013-06-30_PernixTherapeuticsMember" unitRef="USD" decimals="0">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedParties contextRef="AsOf2013-06-30_us-gaap_ExecutiveOfficerMember" unitRef="USD" decimals="0">0</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="AsOf2012-12-31_us-gaap_ExecutiveOfficerMember" unitRef="USD" decimals="0">1272</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">60168</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">56918</us-gaap:LeaseAndRentalExpense>
    <txmd:CapitalLeaseObligationsTerm contextRef="AsOf2013-06-30" unitRef="Months" decimals="INF">63</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2013-06-30_LongTermIncentiveCompensationPlanMember" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2013-06-30_StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:NotesPayable contextRef="AsOf2013-01-31_Debt3Member" unitRef="USD" decimals="0">10000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2012-02-28_DebtMember" unitRef="USD" decimals="0">900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2012-02-24_Debt1Member" unitRef="USD" decimals="0">1358014</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2012-02-24_Debt2Member" unitRef="USD" decimals="0">1357110</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2012-06-19_Debt5Member" unitRef="USD" decimals="0">2347128</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2012-06-19_Debt6Member" unitRef="USD" decimals="0">2344179</us-gaap:NotesPayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-06-30_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">14655793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">13733488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-06-30_LongTermIncentiveCompensationPlanMember" unitRef="Shares" decimals="INF">12934725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-06-30_StockIncentivePlanMember" unitRef="Shares" decimals="INF">1625000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-06-30" unitRef="Shares" decimals="INF">-61372</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-61372</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-06-30_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-03-29_EmployeeStockOptionMember_MaximumMember" unitRef="USDPShares" decimals="INF">2.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-03-29_EmployeeStockOptionMember_MinimumMember" unitRef="USDPShares" decimals="INF">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-06-21_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-05-10_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-05-06_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-06-29_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-04-16_us-gaap_EmployeeStockOptionMember_us-gaap_ExecutiveOfficerMember" unitRef="USDPShares" decimals="INF">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-04-16_us-gaap_CallOptionMember_us-gaap_DirectorMember" unitRef="USDPShares" decimals="INF">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-04-16_us-gaap_CallOptionMember_custom_CommitteeChairsMember" unitRef="USDPShares" decimals="INF">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2013-06-30_EmployeeStockOptionMember" unitRef="USD" decimals="0">26038328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2012-12-31_EmployeeStockOptionMember" unitRef="USD" decimals="0">26804117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="Shares" decimals="INF">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2013-05-01to2013-05-31_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2012-03-01to2012-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2013-05-01to2013-05-31_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">833000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1100486</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1124739</us-gaap:InventoryFinishedGoods>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">114538</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">110471</us-gaap:DeferredCostsCurrent>
    <txmd:NotesSurrendered contextRef="From2012-06-18to2012-06-19_Debt4Member" unitRef="USD" decimals="0">2691847</txmd:NotesSurrendered>
    <txmd:NotesSurrendered contextRef="From2012-06-18to2012-06-19_Debt1Member" unitRef="USD" decimals="0">1347128</txmd:NotesSurrendered>
    <txmd:NotesSurrendered contextRef="From2012-06-18to2012-06-19_Debt2Member" unitRef="USD" decimals="0">1344719</txmd:NotesSurrendered>
    <txmd:NotesSurrendered contextRef="From2012-02-23to2012-02-24_DebtMember" unitRef="USD" decimals="0">1700000</txmd:NotesSurrendered>
    <txmd:NotesProceeds contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="USD" decimals="0">1000000</txmd:NotesProceeds>
    <txmd:NotesProceeds contextRef="From2012-06-18to2012-06-19_Debt7Member" unitRef="USD" decimals="0">2000000</txmd:NotesProceeds>
    <txmd:NotesProceeds contextRef="From2012-03-01to2012-05-31_custom_Debt4Member" unitRef="USD" decimals="0">3000000</txmd:NotesProceeds>
    <txmd:Notes0224AccruedInterestForfeited contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="USD" decimals="0">15124</txmd:Notes0224AccruedInterestForfeited>
    <txmd:Warrants0224Modification contextRef="From2012-02-23to2012-02-24_Debt4Member_Warrants1Member" unitRef="Shares" decimals="INF">5685300</txmd:Warrants0224Modification>
    <txmd:WarrantsIssuedNotes contextRef="From2012-02-23to2012-02-24_Debt4Member_Warrants2Member" unitRef="Shares" decimals="INF">3314700</txmd:WarrantsIssuedNotes>
    <txmd:WarrantsExercisePrice contextRef="From2013-01-30to2013-01-31_Debt3Member" unitRef="USDPUnit" decimals="INF">3.20</txmd:WarrantsExercisePrice>
    <txmd:WarrantsExercisePrice contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="USDPUnit" decimals="INF">0.38</txmd:WarrantsExercisePrice>
    <txmd:WarrantsExercisePrice contextRef="From2012-06-18to2012-06-19_Debt7Member_Warrants1Member" unitRef="USDPUnit" decimals="INF">2.00</txmd:WarrantsExercisePrice>
    <txmd:WarrantsExercisePrice contextRef="From2012-06-18to2012-06-19_Debt7Member_Warrants2Member" unitRef="USDPUnit" decimals="INF">3.00</txmd:WarrantsExercisePrice>
    <txmd:WarrantsExercisePrice contextRef="From2012-02-23to2012-02-24_Debt4Member_Warrants1Member" unitRef="USDPUnit" decimals="INF">0.38</txmd:WarrantsExercisePrice>
    <txmd:WarrantsExercisePrice contextRef="From2012-02-23to2012-02-24_Debt4Member_Warrants2Member" unitRef="USDPUnit" decimals="INF">0.38</txmd:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:Cash contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">34435468</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1553474</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">126421</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1327013</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">957779</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">606641</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1506059</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1615210</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">3607283</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">751938</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">40506589</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4527263</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">156949</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">31949</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">2482706</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1225159</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">43065789</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5818095</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">76494</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">65673</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">4598918</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3511988</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1334730</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">725870</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1219072</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1144752</us-gaap:DeferredRevenue>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">2045116</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1641366</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3739235</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermNotesPayable contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3589167</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">4598918</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">7251223</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">102834270</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">50580400</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">131213</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">99785</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">-64498612</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-52113313</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">38466871</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-1433128</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">43065789</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5818095</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CostOfGoodsSold contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">843952</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-01-01to2012-06-30_PernixTherapeuticsMember" unitRef="USD" decimals="0">96250</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2013-01-01to2013-06-30_PernixTherapeuticsMember" unitRef="USD" decimals="0">0</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">708494</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">463606</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">372370</us-gaap:CostOfGoodsSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-06-30" unitRef="Shares" decimals="INF">29411765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-04-11to2013-04-12_custom_UnderwriterMember" unitRef="Shares" decimals="INF">1954587</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-06-30" unitRef="Shares" decimals="INF">131212706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">6251</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">1179912</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">529129</us-gaap:ShareBasedCompensation>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">6900000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2013-02-01to2013-02-28_LineOfCreditMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2011-03-01to2011-03-31_LineOfCreditMember" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">4691847</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">50780</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-03-20to2013-03-21_Debt7Member" unitRef="USD" decimals="0">-4882019</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">48512460</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-04-11to2013-04-12_custom_UnderwriterMember" unitRef="USD" decimals="0">3100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">291035</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">380000</us-gaap:InventoryRawMaterials>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2013-08-07" unitRef="Shares" decimals="INF">131212706</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">345238</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">239555</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-12-31_PatentsMember" unitRef="USD" decimals="0">224971</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-06-30_PatentsMember" unitRef="USD" decimals="0">337163</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-12-31_WebsiteMember" unitRef="USD" decimals="0">14584</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-06-30_WebsiteMember" unitRef="USD" decimals="0">8075</us-gaap:FiniteLivedIntangibleAssetsGross>
    <txmd:SharesExchangedVitaMed contextRef="From2011-10-01to2011-10-02" unitRef="Shares" decimals="INF">70000000</txmd:SharesExchangedVitaMed>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">149178</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">126273</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31_EquipmentMember" unitRef="USD" decimals="0">67668</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-06-30_EquipmentMember" unitRef="USD" decimals="0">90573</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">46625</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-06-30_FurnitureAndFixturesMember" unitRef="USD" decimals="0">46625</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31_LeaseholdImprovementsMember" unitRef="USD" decimals="0">11980</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-06-30_LeaseholdImprovementsMember" unitRef="USD" decimals="0">11980</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-12-31_WebsiteMember" unitRef="USD" decimals="0">77159</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-06-30_WebsiteMember" unitRef="USD" decimals="0">83668</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">228877</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">397210</us-gaap:AccruedSalariesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">86540</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">53002</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2013-01-31_Debt3Member" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2012-02-28_DebtMember" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2012-06-19_Debt1Member" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2012-06-19_Debt2Member" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-03-31_LineOfCreditMember" unitRef="Pure" decimals="INF">0.03020</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice contextRef="AsOf2013-06-30" unitRef="USDPShares" decimals="INF">1.70</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2013-06-30_WarrantMember" unitRef="Shares" decimals="INF">14293499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2012-12-31_WarrantMember" unitRef="Shares" decimals="INF">12193499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2013-06-30_WarrantMember" unitRef="USD" decimals="0">3995000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <txmd:WarrantsFairValue contextRef="AsOf2013-01-31_Debt3Member" unitRef="USD" decimals="0">1711956</txmd:WarrantsFairValue>
    <txmd:WarrantsFairValue contextRef="AsOf2012-06-19_Debt7Member" unitRef="USD" decimals="0">9424982</txmd:WarrantsFairValue>
    <txmd:WarrantsFairValue contextRef="AsOf2012-02-24_Debt4Member_Warrants2Member" unitRef="USD" decimals="0">6124873</txmd:WarrantsFairValue>
    <txmd:WarrantsFairValue contextRef="AsOf2012-02-24_Debt4Member_Warrants1Member" unitRef="USD" decimals="0">10505247</txmd:WarrantsFairValue>
    <txmd:WarrantsFairValue contextRef="AsOf2013-05-10_custom_SancilioMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">405066</txmd:WarrantsFairValue>
    <txmd:WarrantsFairValue contextRef="AsOf2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">462196</txmd:WarrantsFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.4077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.3335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.4601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.4576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <txmd:WarrantsIssuedNote contextRef="From2013-01-30to2013-01-31_Debt3Member" unitRef="Shares" decimals="INF">1250000</txmd:WarrantsIssuedNote>
    <txmd:WarrantsIssuedNote contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="Shares" decimals="INF">9000000</txmd:WarrantsIssuedNote>
    <txmd:WarrantsIssuedNote contextRef="From2012-06-18to2012-06-19_Debt7Member" unitRef="Shares" decimals="INF">7000000</txmd:WarrantsIssuedNote>
    <txmd:WarrantsIssuedNote contextRef="From2012-06-18to2012-06-19_Debt7Member_Warrants1Member" unitRef="Shares" decimals="INF">6000000</txmd:WarrantsIssuedNote>
    <txmd:WarrantsIssuedNote contextRef="From2012-06-18to2012-06-19_Debt7Member_Warrants2Member" unitRef="Shares" decimals="INF">1000000</txmd:WarrantsIssuedNote>
    <us-gaap:ProfessionalFees contextRef="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">405066</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2012-03-01to2012-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">29736</us-gaap:ProfessionalFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">1583677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-03-28to2013-03-29_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">180109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">632500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-05-09to2013-05-10_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-05-05to2013-05-06_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">96068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-04-15to2012-04-16_us-gaap_EmployeeStockOptionMember_us-gaap_ExecutiveOfficerMember" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-04-15to2012-04-16_us-gaap_CallOptionMember_us-gaap_DirectorMember" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-04-15to2012-04-16_us-gaap_CallOptionMember_custom_CommitteeChairsMember" unitRef="Shares" decimals="INF">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2013-01-01to2013-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ChiefExecutiveOfficerMember" unitRef="Shares" decimals="INF">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="USDPShares" xsi:nil="true" />
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="AsOf2013-06-30_EmployeeStockOptionMember">P7Y9M18D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="AsOf2012-12-31_EmployeeStockOptionMember">P7Y8M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-01-01to2013-06-30">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember">P9Y10M24D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-03-28to2013-03-29_EmployeeStockOptionMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-05-09to2013-05-10_us-gaap_EmployeeStockOptionMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-05-05to2013-05-06_us-gaap_EmployeeStockOptionMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2012-04-15to2012-04-16_us-gaap_EmployeeStockOptionMember_us-gaap_ExecutiveOfficerMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2012-04-15to2012-04-16_us-gaap_CallOptionMember_us-gaap_DirectorMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2012-04-15to2012-04-16_us-gaap_CallOptionMember_custom_CommitteeChairsMember">P10Y</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">3695420</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2013-01-01to2013-06-30">P1Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:Revenues contextRef="From2013-01-01to2013-06-30_us-gaap_ExecutiveOfficerMember" unitRef="USD" decimals="0">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-01-01to2012-06-30_us-gaap_ExecutiveOfficerMember" unitRef="USD" decimals="0">1440</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-06-30_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-06-30_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-06-30_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-06-30_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.62</us-gaap:ConcentrationRiskPercentage1>
    <txmd:MonthlyBaseRentOfLeases contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">28442</txmd:MonthlyBaseRentOfLeases>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2012-06-18to2012-06-19_Debt4Member" unitRef="Shares" decimals="INF">8145486</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtIssuanceCosts contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">659968</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtIssuanceCosts contextRef="From2012-06-18to2012-06-19_Debt7Member" unitRef="USD" decimals="0">1649890</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">395981</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1051988</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2013-06-30_WarrantMember" unitRef="Shares" decimals="INF">12149559</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2013-06-30_LineOfCreditMember" unitRef="Shares" decimals="INF">562571</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-06-30_WarrantMember" unitRef="USDPUnit" decimals="INF">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-12-31_WarrantMember" unitRef="USDPUnit" decimals="INF">1.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-06-30_WarrantMember_MinimumMember" unitRef="USDPUnit" decimals="INF">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-06-30_WarrantMember_MaximumMember" unitRef="USDPUnit" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="USDPUnit" decimals="INF">2.72</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants>
    <txmd:ClassOfWarrantOrRighstContractualLife contextRef="AsOf2013-06-30_WarrantMember">P4Y9M18D</txmd:ClassOfWarrantOrRighstContractualLife>
    <txmd:ClassOfWarrantOrRighstContractualLife contextRef="AsOf2012-12-31_WarrantMember">P4Y9M18D</txmd:ClassOfWarrantOrRighstContractualLife>
    <txmd:ClassOfWarrantOrRighstContractualLifeGrants contextRef="From2013-01-01to2013-06-30_WarrantMember">P7Y8M12D</txmd:ClassOfWarrantOrRighstContractualLifeGrants>
    <us-gaap:CompensatingBalanceAmount contextRef="AsOf2013-02-28_LineOfCreditMember" unitRef="USD" decimals="0">100000</us-gaap:CompensatingBalanceAmount>
    <us-gaap:CompensatingBalanceAmount contextRef="AsOf2011-03-31_LineOfCreditMember" unitRef="USD" decimals="0">100000</us-gaap:CompensatingBalanceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1054658</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-06-18to2012-06-19_Debt4Member" unitRef="USD" decimals="0">3102000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <txmd:SharePrice1 contextRef="AsOf2013-06-30" unitRef="USDPShares" decimals="INF">1.581</txmd:SharePrice1>
    <txmd:OptionsToPurchaseSharesGrantedToUnderwriter contextRef="From2013-01-01to2013-06-30" unitRef="Shares" decimals="INF">4411765</txmd:OptionsToPurchaseSharesGrantedToUnderwriter>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-30to2013-01-31_Debt3Member">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-02-23to2012-02-24_Debt4Member">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-06-18to2012-06-19_Debt7Member">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-06-29to2013-06-30_custom_SancilioMember_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-03-01to2012-03-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-30to2013-01-31_Debt3Member" unitRef="Pure" decimals="INF">0.4429</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="Pure" decimals="INF">0.4450</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-06-18to2012-06-19_Debt7Member" unitRef="Pure" decimals="INF">0.4464</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.4584</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-03-01to2012-03-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.4481</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-30to2013-01-31_Debt3Member" unitRef="Pure" decimals="INF">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="Pure" decimals="INF">0.0089</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-06-18to2012-06-19_Debt7Member" unitRef="Pure" decimals="INF">0.0075</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0141</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-03-01to2012-03-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-01-30to2013-01-31_Debt3Member" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-02-23to2012-02-24_Debt4Member" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-06-18to2012-06-19_Debt7Member" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-03-01to2012-03-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <txmd:FirstUnitedGuaranteesWarrants contextRef="From2011-03-01to2011-03-31_LineOfCreditMember" unitRef="Shares" decimals="INF">613713</txmd:FirstUnitedGuaranteesWarrants>
    <txmd:WarrantsAmendedWarrantsVestedPriorToAmendment contextRef="From2012-11-12to2012-11-13_LineOfCreditMember" unitRef="Shares" decimals="INF">358000</txmd:WarrantsAmendedWarrantsVestedPriorToAmendment>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2012-12-31_PernixTherapeuticsMember" unitRef="USD" decimals="0">0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2013-06-30_PernixTherapeuticsMember" unitRef="USD" decimals="0">171261</us-gaap:DueFromRelatedParties>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1791900</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2013-06-30_WarrantMember" unitRef="USD" decimals="0">17985449</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2012-12-31_WarrantMember" unitRef="USD" decimals="0">17971994</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <us-gaap:RepaymentsOfDebt contextRef="From2013-03-01to2013-03-31_Debt3Member" unitRef="USD" decimals="0">401085</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-02-01to2013-02-28_Debt3Member" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-03-01to2013-03-31_Debt3Member" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Other current assets consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid research and development costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,686,254&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;189,375&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,051,988&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid consulting&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;541,936&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;432,216&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other receivables-related party (Note 12)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;171,261&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid insurance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;125,266&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;127,403&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other prepaid costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;30,578&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid guaranty costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,944&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL OTHER CURRENT ASSETS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,607,283&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;751,938&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Intangible assets consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Patent costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;337,163&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;224,971&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -18pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Website costs, net of amortization of $83,668 and $77,159, respectively&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;8,075&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,584&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -18pt; display: block; margin-left: 27pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL INTANGIBLE ASSETS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;345,238&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;239,555&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Other current liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued offering costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued payroll and commission costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;228,877&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;397,210&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued vacation costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;263,851&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;114,899&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued professional fees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;120,250&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;90,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Allowance for coupons and returns&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;86,540&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;53,002&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;93,853&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;29,400&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividends payable&lt;font style="display: inline; font-size: 70%; vertical-align: text-top"&gt;(1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;41,359&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;41,359&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,334,730&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;725,870&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;______________&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-size: 70%; vertical-align: text-top"&gt;(1) &lt;/font&gt;In June 2008, the Company declared and paid a special dividend of $0.40 per share of common stock to all stockholders of record as of June 10, 2008.&amp;#160;&amp;#160;This amount reflects unclaimed dividends by certain stockholders.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <dei:EntityRegistrantName contextRef="From2013-01-01to2013-06-30">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2013-01-01to2013-06-30">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2013-01-01to2013-06-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2013-01-01to2013-06-30">2013-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2013-01-01to2013-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2013-01-01to2013-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2013-01-01to2013-06-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2013-01-01to2013-06-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2013-01-01to2013-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2013-01-01to2013-06-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2013-01-01to2013-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2013-01-01to2013-06-30">2013</dei:DocumentFiscalYearFocus>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1980519</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">953655</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">150068</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">3618080</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1540842</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">2080885</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">819150</us-gaap:SalesRevenueNet>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">2774128</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">832348</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">1617279</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">446780</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">10003135</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">6400535</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">5476553</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">3573485</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">3312285</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1245303</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">1747084</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">833342</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">18593</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">29113</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">10636</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">14535</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">13334013</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">7674951</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">7234273</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">4421362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-10559885</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-6842603</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">-5616994</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-3974582</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">3479</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1554</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">3479</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">1554</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">1165981</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1250734</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">150</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">1148761</us-gaap:InterestExpense>
    <txmd:LoanGuarantyCosts contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">2944</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">23490</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2013-04-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <txmd:LoanGuarantyCosts contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">11745</txmd:LoanGuarantyCosts>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-6716504</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2013-04-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-6716504</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-10307864</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2013-04-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-1825414</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-18297038</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">-392652</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-7875456</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-12385299</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-25139641</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">-6009646</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-11850038</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-04-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-12385299</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-25139641</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">-6009646</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-11850038</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-06-30" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-04-01to2013-06-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-04-01to2012-06-30" unitRef="USDPShares" decimals="INF">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-06-30" unitRef="Shares" decimals="INF">116866764</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">85352818</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-04-01to2013-06-30" unitRef="Shares" decimals="INF">130851978</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-04-01to2012-06-30" unitRef="Shares" decimals="INF">86149419</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">12084</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">15141</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">6509</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">13972</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">58337</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">15023</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">659938</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">637155</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">120120</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">409475</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">396232</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-109151</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">232168</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">1696551</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">118566</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">899000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">403750</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">385620</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-150068</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">133702</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">608860</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">248450</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:DeferredRevenueAdditions contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-74320</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-618877</us-gaap:DeferredRevenueAdditions>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-10684753</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-5649439</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForDeposits contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">125000</us-gaap:PaymentsForDeposits>
    <us-gaap:PaymentsForDeposits contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">112192</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">49184</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">22905</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">66404</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-260097</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-115588</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-50000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">6231</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">165999</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">-500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="From2013-04-24to2013-04-25_LineOfCreditMember" unitRef="USD" decimals="0">100735</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">400</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">43826844</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">6965619</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">32881994</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1200592</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">212853</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">7756</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <txmd:WarrantsIssuedForFinancing contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancing>
    <txmd:WarrantsIssuedForFinancing contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">2509537</txmd:WarrantsIssuedForFinancing>
    <txmd:WarrantsIssuedInExchangeForDebt contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <txmd:WarrantsIssuedInExchangeForDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">3102000</txmd:WarrantsIssuedInExchangeForDebt>
    <txmd:WarrantsIssuedForServices contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">462196</txmd:WarrantsIssuedForServices>
    <txmd:WarrantsIssuedForServices contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1532228</txmd:WarrantsIssuedForServices>
    <us-gaap:NotesIssued1 contextRef="From2013-01-01to2013-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesIssued1 contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">15123</us-gaap:NotesIssued1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-06-30" unitRef="Shares" decimals="INF">21773002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">18884154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">30578</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1686254</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">189375</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">171261</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">899000</txmd:PrepaidManufacturingCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:PrepaidConsultingNoncurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">1081519</txmd:PrepaidConsultingNoncurrent>
    <txmd:PrepaidConsultingNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">953655</txmd:PrepaidConsultingNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2013-06-30" unitRef="USD" decimals="0">120250</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">90000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2013-03-31_custom_Debt7Member" unitRef="USD" decimals="0">21595</us-gaap:InterestPayableCurrent>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="USDPUnit" xsi:nil="true" />
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="USDPUnit" xsi:nil="true" />
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="USDPUnit" xsi:nil="true" />
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable contextRef="AsOf2013-06-30_WarrantMember" unitRef="USDPUnit" decimals="INF">1.67</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable>
    <txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable contextRef="AsOf2013-06-30_WarrantMember">P4Y8M12D</txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue contextRef="AsOf2013-06-30_WarrantMember" unitRef="USD" decimals="0">16540175</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue contextRef="From2013-01-01to2013-06-30_WarrantMember" unitRef="USD" decimals="0">867000</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2013-06-30_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">9623443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-06-30_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2013-06-30_EmployeeStockOptionMember" unitRef="USD" decimals="0">23208051</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">45400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="AsOf2013-06-30_custom_Debt3Member" unitRef="USD" decimals="0">1051988</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther contextRef="From2013-05-09to2013-05-10_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther contextRef="From2013-06-29to2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">154068</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">308128</us-gaap:PrepaidExpenseNoncurrent>
    <txmd:UnvestedWarrants contextRef="AsOf2013-06-30_custom_SancilioMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">283334</txmd:UnvestedWarrants>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-03-28to2013-03-29_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">31250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-05-09to2013-05-10_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember_custom_Vesting3YearsAnnualMember" unitRef="Shares" decimals="INF">232500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember_custom_Vesting18monthsMember" unitRef="Shares" decimals="INF">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-06-20to2013-06-21_us-gaap_EmployeeStockOptionMember_custom_Vesting3YearsMonthlyMember" unitRef="Shares" decimals="INF">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-05-09to2013-05-10_custom_Vesting4YearsAnnualMember" unitRef="Shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-05-05to2013-05-06_custom_Vesting12monthsMember" unitRef="Shares" decimals="INF">96068</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-03-28to2013-03-29_custom_Vesting4YearsAnnualMember" unitRef="Shares" decimals="INF">500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-03-28to2013-03-29_custom_Vesting12monthsMember" unitRef="Shares" decimals="INF">12500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-03-28to2013-03-29_custom_Vesting13monthsMember" unitRef="Shares" decimals="INF">92109</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2013-03-28to2013-03-29_custom_Vesting7monthsMember" unitRef="Shares" decimals="INF">43750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_Vesting4YearsAnnualMember" unitRef="Shares" decimals="INF">7500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_Vesting2YearsAnnualMember" unitRef="Shares" decimals="INF">115000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_Vesting12monthsMember" unitRef="Shares" decimals="INF">2500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2012-06-28to2012-06-29_us-gaap_EmployeeStockOptionMember_custom_VestingMonthly123112Member" unitRef="Shares" decimals="INF">75000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <txmd:DirectorsStockOptionsAuthorized contextRef="From2013-01-01to2013-06-30" unitRef="Shares" decimals="INF">575000</txmd:DirectorsStockOptionsAuthorized>
    <txmd:DirectorsStockOptionsAuthorized contextRef="From2013-05-01to2013-05-02_us-gaap_BoardOfDirectorsChairmanMember" unitRef="Shares" decimals="INF">225000</txmd:DirectorsStockOptionsAuthorized>
    <txmd:DirectorsStockOptionsAuthorized contextRef="From2013-05-01to2013-05-02_custom_CommitteeChairsMember" unitRef="Shares" decimals="INF">75000</txmd:DirectorsStockOptionsAuthorized>
    <txmd:DirectorsStockOptionsAuthorized contextRef="From2013-05-01to2013-05-02_us-gaap_DirectorMember" unitRef="Shares" decimals="INF">50000</txmd:DirectorsStockOptionsAuthorized>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 1 &amp;#8211; THE COMPANY&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. &lt;font style="display: inline"&gt;Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as &amp;#8220;our company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our,&amp;#8221; or &amp;#8220;us.&amp;#8221;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Nature of Business&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We are a women&amp;#8217;s healthcare product company focused on creating and commercializing products targeted exclusively for women.&amp;#160;&amp;#160;We currently manufacture and distribute branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 2 &amp;#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING &lt;/font&gt;&lt;/font&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;PRONOUNCEMENTS&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Interim Financial Statements&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Our accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles, or GAAP, for complete financial statements.&amp;#160;&amp;#160;In our opinion, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC.&amp;#160;&amp;#160;The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.&amp;#160;&amp;#160;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period.&amp;#160;&amp;#160;Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC 820 &lt;font style="font-style: italic; display: inline"&gt;Fair Value Measurements and Disclosures. &lt;/font&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&amp;#160;&amp;#160;Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%; text-align: center"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: top; width: 82%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: top; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 82%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%; text-align: center"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 82%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 82%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%; text-align: center"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: top; width: 82%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;unobservable inputs for the asset or liability.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;At June 30, 2013 and December 31, 2012, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Research and Development&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Research and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, external contract research organization, or CRO, services and their clinical research sites, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and share-based compensation expenses.&amp;#160;&amp;#160;CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel.&amp;#160;&amp;#160;Internal R&amp;#38;D activities and other activity expenses are charged to operations as incurred.&amp;#160;&amp;#160;We make payments to the CRO&amp;#8217;s based on agreed upon terms and may include payments in advance of a study starting date.&amp;#160;&amp;#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&amp;#160;&amp;#160;We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO.&amp;#160;&amp;#160;Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Earnings Per Share&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We calculate earnings per share, or EPS, in accordance with ASC 260, &lt;font style="font-style: italic; display: inline"&gt;Earnings Per Share&lt;/font&gt;, which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of common stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potentially dilutive common shares consist of stock options and warrants. Potentially dilutive common shares totaling 21,773,002 and 18,884,154 at June 30, 2013 and 2012, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Recently Issued and Newly Adopted Accounting Pronouncements&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On July 18, 2013, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2013-11, &lt;font style="font-style: italic; display: inline"&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force)&lt;/font&gt;. The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have an impact on our condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Reclassifications&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Certain 2012 amounts have been reclassified to conform to current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 3 &amp;#8211; INVENTORY&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Inventory consists of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Finished product&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,100,486&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,124,739&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Raw material&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;291,035&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;380,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Deferred costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;114,538&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;110,471&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL INVENTORY&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,506,059&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,615,210&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 4 &amp;#8211; OTHER CURRENT ASSETS&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Other current assets consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid research and development costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,686,254&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;189,375&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Deferred financing costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,051,988&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid consulting&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;541,936&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;432,216&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other receivables-related party (Note 12)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;171,261&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid insurance&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;125,266&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;127,403&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other prepaid costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;30,578&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Prepaid guaranty costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,944&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL OTHER CURRENT ASSETS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,607,283&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;751,938&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 5 &amp;#8211; FIXED ASSETS&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Fixed assets consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;90,573&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;67,668&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;46,625&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;46,625&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;11,980&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;11,980&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;149,178&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;126,273&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accumulated depreciation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(72,684&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(60,600&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL FIXED ASSETS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;76,494&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;65,673&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Depreciation expense for the six months ended June 30, 2013 and 2012 was $12,084 and $15,141, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 7 &amp;#8211; OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Other current liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued offering costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued payroll and commission costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;228,877&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;397,210&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued vacation costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;263,851&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;114,899&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accrued professional fees&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;120,250&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;90,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Allowance for coupons and returns&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;86,540&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;53,002&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;93,853&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;29,400&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividends payable&lt;font style="display: inline; font-size: 70%; vertical-align: text-top"&gt;(1)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;41,359&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;41,359&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,334,730&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;725,870&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;______________&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 27pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-size: 70%; vertical-align: text-top"&gt;(1) &lt;/font&gt;In June 2008, the Company declared and paid a special dividend of $0.40 per share of common stock to all stockholders of record as of June 10, 2008.&amp;#160;&amp;#160;This amount reflects unclaimed dividends by certain stockholders.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 8 &amp;#8211; NOTES PAYABLE&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Issuance and Payment of Multiple Advance Revolving Credit Note&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, a Florida limited liability company, or Plato, for a Multiple Advance Revolving Credit Note, or the Plato Note.&amp;#160;&amp;#160;The Plato Note allows us to draw down funding up to the $10 million maximum principal amount, at a stated interest rate of 6% per annum.&amp;#160;&amp;#160;Plato may make advances to us from time to time under the Plato Note at our request, which advances will be of a revolving nature and may be made, repaid, and made from time to time.&amp;#160;&amp;#160;Interest payments shall be due and payable on the tenth day following the end of each calendar quarter in which any interest is accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Plato Note, together with all accrued interest and other amounts payable under the Plato Note, if any, will be due and payable on February 24, 2014.&amp;#160;&amp;#160;The Plato Note is secured by substantially all of our assets.&amp;#160;&amp;#160;On each of February 25 and March 13, 2013, $200,000 was drawn against the Plato Note. On March 21, 2013, we repaid $401,085, including accrued interest, and as of June 30, 2013, there was no balance outstanding under the Plato Note.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As additional consideration for the Plato Note, we issued Plato a warrant to purchase 1,250,000 shares of our common stock at an exercise price $3.20 per share (see &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;NOTE 9 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt; for more details).&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Borrowing Under Amended Bank LOC&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In February 2013, we borrowed $100,000 from First United Bank under the Amended Bank LOC. The Amended Bank LOC required a personal guarantee and cash collateral limited to $100,000 which was provided by Reich Family Limited Partnership, or Reich Family LP, an entity controlled by Mitchell Krassan, an officer of the Company.&amp;#160;&amp;#160;On April 25, 2013, we paid the principal and interest due under the Amended Bank LOC of $100,735.&amp;#160;&amp;#160;On May 1, 2013, the Amended Bank LOC expired and was not renewed.&amp;#160;&amp;#160;Accordingly, the personal guarantee was canceled and the cash collateral was refunded to Reich Family LP.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Issuance of Promissory Notes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In January and February 2012, we sold 6% promissory notes for an aggregate of $900,000 with due dates of March 1, 2012.&amp;#160;&amp;#160;As discussed below in &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;Issuance and Settlement of February 2012 Notes&lt;/font&gt;, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory notes, or the February 2012 Notes.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Issuance and Settlement of February 2012 Notes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On February 24, 2012, we issued the February 2012 Notes to an individual and an entity, or the Parties, both of which are our stockholders, in the principal base amount of $1,358,014 and $1,357,110, respectively, and granted warrants for the purchase in the aggregate of 9,000,000 shares of our common stock, or the February 2012 Warrants, pursuant to the terms of a Note Purchase Agreement, also dated February 24, 2012.&amp;#160;&amp;#160;As consideration for the February 2012 Notes and the February 2012 Warrants, we received an aggregate of $1,000,000 of new funding from the Parties and the Parties surrendered certain promissory notes previously issued by us in the aggregate amount of $1,700,000 plus accrued interest of $15,124. Under the February 2012 Notes, the Parties loaned us an additional $3,000,000 during March, April, and May 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On June 19, 2012, we settled $3,102,000 in principle and interest of the February 2012 Notes in exchange for the exercise of 8,145,486 warrants. As discussed below in &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;Issuance and Payment of June 2012 Notes&lt;/font&gt;, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the June 2012 Notes, (see &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;NOTE 9 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;, &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;Warrants Issued in Connection with Debt&lt;/font&gt;&lt;font style="display: inline; text-decoration: underline"&gt;,&lt;/font&gt; for more details).&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Issuance and Payment of June 2012 Notes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On June 19, 2012, we issued the June 2012 Notes to the Parties in the principal base amounts of $2,347,128 and $2,344,719,&lt;font style="display: inline; font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;respectively, pursuant to the terms of a note purchase agreement, or the June 2012 Note Purchase Agreement. &lt;font style="display: inline; font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;As consideration for the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively (which sums included principle and interest through June 19, 2012), and we received an aggregate of $2,000,000 of new funding from the Parties (the &amp;#8220;June Funding&amp;#8221;).&amp;#160;&amp;#160;The principal base amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June 2012 Note Purchase Agreement and the June 2012 Notes, we entered into a security agreement and pledged all of our assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares of our common stock in connection with the June Funding.&amp;#160;&amp;#160;On March 21, 2013, we repaid $4,882,019 including accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013 related to the June 2012 Notes.&amp;#160;&amp;#160;On April 25, 2013, the balance of accrued interest was paid in full.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 10 &amp;#8211; INCOME TAXES&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2013 as a result of (i) the losses recorded during the six months ended June 30, 2013, (ii) additional losses expected for the remainder of 2013, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &amp;#8220;more likely than not" that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2013, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 11 &amp;#8211; RELATED PARTIES&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Loan Guaranty&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note for a $300,000 bank line of credit, or the Bank LOC, for which the bank required personal guarantees and cash collateral. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family LP, an entity controlled by Mitchell Krassan, also an officer of VitaMed.&amp;#160;&amp;#160;The Bank LOC accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.&amp;#160;&amp;#160;On March 19, 2012, the bank and VitaMed negotiated a one year extension to the Bank LOC and a subsequent 2-month extension until May 1, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In consideration for the personal guarantees and cash collateral, we issued warrants for an aggregate of 613,713 shares.&amp;#160;&amp;#160;On November 13, 2012, we entered into an amendment with the bank to reduce the Bank LOC to $100,000, or the Amended Bank LOC. As part of the Amended Bank LOC, the personal guarantees and cash collateral for Mr. Finizio and Mr. Milligan were released.&amp;#160;&amp;#160;In accordance with the terms of the warrants, the warrants previously granted to Mr. Finizio and Mr. Milligan were amended to reflect the amount vested prior to the date of the Amended Bank LOC (179,000 each).&amp;#160;&amp;#160;At June 30, 2013, an aggregate of 562,571 warrants related to this loan guaranty were vested.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In February 2013, we borrowed $100,000 under the Amended Bank LOC.&amp;#160;&amp;#160;The Amended Bank LOC required a personal guarantee and cash collateral limited to $100,000 which was provided by Reich Family LP.&amp;#160;&amp;#160;&amp;#160;On April 25, 2013, we paid the principal and interest due under the Amended Bank LOC of $100,735. On May 1, 2013, the Amended Bank LOC expired and was not renewed. Accordingly, the personal guarantee was canceled and the cash collateral was returned to Reich Family LP&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Lock-Up Agreements&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As required by the terms of the merger agreement with VitaMed dated July 18, 2011, the Company entered into Lock-Up Agreements, or the Agreements, with stockholders covering the aggregate of 70,000,000 shares of our common stock issued pursuant to this merger or reserved for issuance pursuant to stock options and warrants. Each stockholder agreed that from the date of the Agreements until 18 months thereafter, or the Lock-Up Period, they would not make or cause any sale of our common stock.&amp;#160;&amp;#160;After the completion of the Lock-Up Period, each stockholder agreed not to sell or dispose of more than 2.5% of their aggregate common stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period.&amp;#160;&amp;#160;Upon the completion of the Dribble Out Period, the Agreements shall terminate.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Purchases by Related Parties&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;During the six months ended June 30, 2013 and 2012, we sold our products to Dr. Brian Bernick, our Chief Medical Officer and director, in the amounts of $0 and $1,440, respectively, while $0 and $1,272 in receivables related thereto remained outstanding at both June 30, 2013 and December 31, 2012, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Agreements with Pernix Therapeutics, LLC&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On February 29, 2012, Cooper C. Collins, President and largest stockholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on the Board.&amp;#160;&amp;#160;The Company entered into a Stock Purchase Agreement with Pernix on October 4, 2011.&amp;#160;&amp;#160;From time to time, we have entered into agreements with Pernix in the normal course of business primarily for the purchase of inventory.&amp;#160;&amp;#160;During the six months ended June 30, 2013 and 2012, we made purchases of approximately $0 and $96,250, respectively, from Pernix.&amp;#160;&amp;#160;At June 30, 2013 and December 31, 2012, there were outstanding amounts due to Pernix of approximately $0 and $308,000, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Additionally, there were amounts due to us from Pernix for legal fee reimbursement in regards to the Aceto litigation described below in the amounts of $171,261 and $0 for the periods ending June 30, 2013 and December 31, 2012, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 12 - BUSINESS CONCENTRATIONS&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We purchase our products from several suppliers with approximately 98% and 87% of our purchases were supplied from one vendor for the six months ended June 30, 2013 and 2012, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to two customers, Cardinal Health, Inc. and McKesson Corporation accounted for 62% and 36% of our recognized revenue for the six months ended June 30, 2013 and 2012, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 13 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Office Lease&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018.&amp;#160;&amp;#160;The lease stipulates, among other things, average base monthly rents of $28,442 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,791,900.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The rental expense related to our prior lease which expired June 30, 2013 totaled $60,168 and $56,918 for the six months ended June 30, 2013 and 2012, respectively.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Litigation&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We are party to various legal actions arising in the ordinary course of business, including actions related to our intellectual property. While it is not feasible to determine the actual outcome of these actions at this time, we do not believe that these matters, including those described below, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="font: italic 10pt Times New Roman; display: inline"&gt;Aceto Corporation&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On November 13, 2012, Aceto Corporation filed a lawsuit against TherapeuticsMD and Boca-Green in the United States District Court for the Southern District of Florida seeking to enjoin us from using the Quatrefolic product and trademarks, among other things. On July, 17, 2013, the Court dismissed Aceto Corporation&amp;#8217;s Complaint with leave to file an Amended Complaint on or before August 5, 2013. Based on our assessment of the case which is in the discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="font: italic 10pt Times New Roman; display: inline"&gt;Avion Pharmaceuticals, LLC&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On November 30, 2012, Avion Pharmaceuticals, LLC, filed a lawsuit against TherapeuticsMD and Boca- Green in the United States District Court for the Northern District of Georgia seeking to enjoin us from using the Prena1 name, among other things. Based on our assessment of the case which is in the discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;For additional information on these litigation matters, see our Annual Report on Form 10-K for the year ended December 31, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Our accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles, or GAAP, for complete financial statements.&amp;#160;&amp;#160;In our opinion, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC.&amp;#160;&amp;#160;The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.&amp;#160;&amp;#160;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period.&amp;#160;&amp;#160;Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2012.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC 820 &lt;font style="font-style: italic; display: inline"&gt;Fair Value Measurements and Disclosures. &lt;/font&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&amp;#160;&amp;#160;Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%; text-align: center"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: top; width: 82%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: top; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 82%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%; text-align: center"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 82%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 82%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 5%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 10%; text-align: center"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: bold 10pt times new roman"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: top; width: 82%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;unobservable inputs for the asset or liability.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;At June 30, 2013 and December 31, 2012, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/font&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Research and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, external contract research organization, or CRO, services and their clinical research sites, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and share-based compensation expenses.&amp;#160;&amp;#160;CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel.&amp;#160;&amp;#160;Internal R&amp;#38;D activities and other activity expenses are charged to operations as incurred.&amp;#160;&amp;#160;We make payments to the CRO&amp;#8217;s based on agreed upon terms and may include payments in advance of a study starting date.&amp;#160;&amp;#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&amp;#160;&amp;#160;We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO.&amp;#160;&amp;#160;Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman"&gt;We&#13;calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation&#13;and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of common&#13;stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of common stock outstanding&#13;plus all potentially dilutive common shares outstanding during the period. Such potentially dilutive common shares consist of&#13;stock options and warrants. Potentially dilutive common shares totaling 21,773,002 and 18,884,154 at June 30, 2013 and 2012, respectively,&#13;have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On July 18, 2013, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2013-11, &lt;font style="font-style: italic; display: inline"&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force)&lt;/font&gt;. The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have an impact on our condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Certain 2012 amounts have been reclassified to conform to current year presentation.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Inventory consists of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Finished product&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,100,486&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,124,739&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Raw material&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;291,035&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;380,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Deferred costs&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;114,538&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;110,471&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL INVENTORY&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,506,059&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,615,210&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Fixed assets consist of the following:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30,&lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;December 31,&lt;br /&gt;&#13;2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Equipment&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;90,573&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;67,668&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;46,625&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;46,625&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;11,980&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;11,980&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;149,178&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;126,273&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Accumulated depreciation&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(72,684&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(60,600&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; text-align: left; padding-bottom: 4px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;TOTAL FIXED ASSETS&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;76,494&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;65,673&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;p style="text-align: justify; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 6 &amp;#8211; OTHER&#13;ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid expense consists&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 2px solid; text-align: center; text-indent: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 2px solid; text-align: center; padding-left: 18pt; text-indent: -18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -18pt; padding-left: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;899,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2px; text-indent: -18pt; padding-left: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2px solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,081,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;953,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4px; text-indent: -18pt; padding-left: 27pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL PREPAID EXPENSE&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,980,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;953,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;Intangible assets consist&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 2px solid; text-align: center; text-indent: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 2px solid; text-align: center; padding-left: 18pt; text-indent: -18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -18pt; padding-left: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Patent costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;337,163&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;224,971&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2px; text-indent: -18pt; padding-left: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Website costs, net of amortization of $83,668 and $77,159, respectively&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2px solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,075&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,584&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4px; text-indent: -18pt; padding-left: 27pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INTANGIBLE ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;345,238&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;239,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;Amortization expense for&#13;the six months ended June 30, 2013 and 2012 was $6,509 and $13,972, respectively.&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2013-01-01to2013-06-30">&lt;p style="text-align: justify; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid expense consists&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 2px solid; text-align: center; text-indent: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 2px solid; text-align: center; padding-left: 18pt; text-indent: -18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -18pt; padding-left: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;899,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2px; text-indent: -18pt; padding-left: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2px solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,081,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;953,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4px; text-indent: -18pt; padding-left: 27pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TOTAL PREPAID EXPENSE&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,980,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: left; border-top: black 2px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4px double; text-align: right; border-top: black 2px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;953,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="From2013-01-01to2013-06-30_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">365845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;NOTE 9 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Common Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: -0.9pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;At June 30, 2013, we had 250,000,000 shares of common stock, $0.001 par value per share, authorized with 131,212,706 shares issued and outstanding.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Public Offering&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 14, 2013, we entered into an underwriting agreement, or the Underwriting Agreement, with Jefferies LLC, as representative of the underwriters named therein, or the Underwriters, relating to the issuance and sale of 29,411,765 shares of our common stock. The price to the public in the offering was $1.70 per share and the Underwriters agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.581 per share. The net proceeds to us from this offering was&amp;#160;&amp;#160;approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.&amp;#160;&amp;#160;In addition, under the terms of the Underwriting Agreement, we granted the Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of common stock. The offering closed on March 20, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Additional Shares Purchased under Offering&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As part of the public offering of our common stock described in &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;Public Offering&lt;/font&gt; above, on April 12, 2013, the Underwriters exercised their option to purchase an additional 1,954,587 shares of our common stock to cover over-allotments.&amp;#160;&amp;#160;We issued these shares to the Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Warrants to Purchase Common Stock of the Company&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of June 30, 2013, we had common stock purchase warrants outstanding for an aggregate of 14,293,499 shares of our common stock with a weighted average contractual remaining life of 4.8 years and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.86 per share.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The valuation methodology used to determine the fair value of our Warrants is the Black-Scholes-Merton option-pricing model, or Black-Scholes Model, an acceptable model in accordance with ASC 718-10, Compensation &amp;#8211; Stock Compensation. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the Warrant.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Warrants Issued in Connection with Debt&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman"&gt;On&#13;January 31, 2013, we granted a warrant for the purchase of 1,250,000 shares of our common stock in connection with&#13;the issuance of the Plato Note, or the Plato Warrant, (see &lt;i&gt;&lt;u&gt;NOTE 8 &amp;#8211; NOTES PAYABLE&lt;/u&gt;, &lt;u&gt;Issuance of&#13;Multiple Advance Revolving Credit Note&lt;/u&gt;&lt;/i&gt;).&amp;#160;&amp;#160;The Plato Warrant has an exercise price of $3.20 per share. The&#13;Plato Warrant will vest and become exercisable on October 31, 2013 and may be exercised any time after that date prior to&#13;the January 31, 2019 expiration date of the Plato Warrant.&amp;#160;&amp;#160;This Warrant, with a fair value of&#13;approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free&#13;rate of 0.88%; and a dividend yield of 0%.&amp;#160;&amp;#160;At June 30, 2013, $1,051,988 was reported as deferred financing costs&#13;included in other current assets in the accompanying condensed consolidated balance sheet and is being amortized over the&#13;life of the Plato Note. For the six months ended June 30, 2013, $659,938 was recorded as financing costs on the accompanying&#13;condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On June 19, 2012, we granted warrants for the purchase of an aggregate of 7,000,000 shares of our common stock in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;NOTE 8 &amp;#8211; NOTES PAYABLE&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;, &lt;/font&gt;&lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;Issuance of June 2012 Notes&lt;/font&gt;). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share.&amp;#160;&amp;#160;The fair value of the June 2012 Warrants of $9,424,982 was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%.&amp;#160;&amp;#160;The relative fair value of the June 2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the grant.&amp;#160;&amp;#160;As a result of the repayment of the associated debt on March 21, 2013, we expensed the remaining unamortized debt discount of $885,709 at the time of the repayment.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On February 24, 2012, we issued warrants for the purchase of an aggregate of 5,685,300 shares of our common stock in connection with the modification of certain existing promissory notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our common stock in connection with the issuance of the February 2012 Notes (the &amp;#8220;February 2012 Warrants&amp;#8221;) (see &lt;font style="font-style: italic; display: inline; text-decoration: underline"&gt;NOTE 8 &amp;#8211; NOTES PAYABLE, Issuance of February 2012 Notes&lt;/font&gt;). Both the Modification Warrants and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants&amp;#8217; fair value of $10,505,247 and the February 2012 Warrants&amp;#8217; fair value of $6,124,873 was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment of debt in the accompanying condensed consolidated financial statements.&amp;#160;&amp;#160;The relative fair value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining unamortized debt discount.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Warrants Issued for Services&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On May 7, 2013, we entered into a consulting agreement, or the Agreement, with Sancilio &amp;#38; Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug Products.&amp;#160;&amp;#160;These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA.&amp;#160;&amp;#160;In connection with the Agreement, SCI agreed to forfeit its rights to receive warrants for the purchase of an aggregate of 833,000 shares of our common stock that were to be issued pursuant to the terms of a prior consulting agreement dated May 17, 2012.&amp;#160;&amp;#160;As consideration under the Agreement, we agreed to issue SCI a warrant to purchase 850,000 shares of our common stock that vest as follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" id="hangingindent" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 5%; width: 36pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 3%; width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 92%"&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;283,333 shares&amp;#160;were earned on May&amp;#160;11, 2013 upon successful filing of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment of VVA.&amp;#160;&amp;#160;The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as consulting expense in the accompanying condensed consolidated financial statements,&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 5%; width: 36pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 3%; width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 92%"&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;283,333 shares vested on June 30, 2013.&amp;#160;&amp;#160;The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. We recorded $154,068 as prepaid expense-short term and $308,128 as prepaid expense-long term in the accompanying condensed consolidated financial statements.&amp;#160;&amp;#160;We will begin amortizing this expense monthly over 3 years beginning in July 2013, and&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt times new roman; width: 100%; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 5%; width: 36pt"&gt;&#13;&lt;div&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 3%; width: 18pt"&gt;&#13;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="width: 92%"&gt;&#13;&lt;div style="text-align: justify"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;283,334 shares will vest upon the receipt by us of any final FDA approval of a Drug Product that SCI helped us design.&amp;#160;&amp;#160;It is anticipated that this event will not occur before December 2015.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In March 2012, we issued a warrant for the purchase of an aggregate of 31,000 shares of our common stock to five unaffiliated individuals for services rendered. These warrants were valued on the date of the grant using a term of 5 years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; $29,736 was recorded as consulting expense in the accompanying condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;A summary of our warrant activity and related information for 2013 follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Number of&lt;br /&gt;&#13;Shares&lt;br /&gt;&#13;Under Company Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Average&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Life in Years&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Intrinsic &lt;br /&gt;&#13;Value&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at December 31, 2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;12,193,499&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.63&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;17,971,994&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,100,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.72&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.3&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;867,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expired&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at June 30, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,293,499&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.79&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;17,985,449&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vested and Exercisable at &lt;/font&gt;June 30, 2013&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;12,149,559&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.67&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4.3&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;16,540,175&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;As of June 30, 2013, we had warrants outstanding with exercise prices ranging from $0.24 to $3.20 per share. As of June 30, 2013, unamortized costs associated with warrants totaled approximately $3,995,000.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; text-decoration: underline"&gt;Stock Options&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or LTIP, to provide financial incentives to our employees, members of our Board, and our advisers and consultants who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the LTIP consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, EVA awards, and other stock or cash awards as described in the LTIP. There are 25,000,000 shares authorized for issuance under the LTIP. Under this LTIP, non-qualified stock options for the purchase of an aggregate of 12,934,725 shares of our common stock were outstanding at June 30, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On February 23, 2012, the Board adopted the 2012 Stock Incentive Plan, a non-qualified plan not requiring approval by our stockholders, or the 2012 SOP.&amp;#160;&amp;#160;The 2012 SOP was designed to serve as an incentive for retaining qualified and competent key employees, officers and directors, and certain consultants and advisors.&amp;#160;&amp;#160;There are 10,000,000 shares authorized for issuance under the 2012 SOP and non-qualified stock options for the purchase of an aggregate of 1,625,000 shares of our common stock were outstanding at June 30, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The valuation methodology used to determine the fair value of the stock options is the Black-Scholes Model.&amp;#160;&amp;#160;The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the six months ended June 30, 2013 are set forth in the table below.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Six Months&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Year Ended December 31, 2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.65-1.42&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.61-2.23&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33.35-45.76&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;40.77-46.01&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life.&amp;#160;&amp;#160;Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards.&amp;#160;&amp;#160;We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price.&amp;#160;&amp;#160;The average expected life is based on the contractual term of the option using the simplified method.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On June 28, 2013, an individual exercised his stock option to purchase an aggregate of 61,372 shares of our common stock for an aggregate purchase price of $6,251.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On June 21, 2013, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 632,500 shares with an exercise price of $2.98.&amp;#160;&amp;#160;An aggregate of 232,500 shares available under the stock options vest over a 3-year period on the anniversary of issuance, an aggregate of 100,000 shares vest monthly over an 18 month period, and an aggregate of 300,000 shares vest monthly over a 3-year period.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On May 10, 2013, we issued 10-year stock options to employees for the purchase of an aggregate of 100,000 shares with an exercise price of $2.71.&amp;#160;&amp;#160;An aggregate of 50,000 shares available under the stock options vest over a 4-year period on the anniversary of issuance and an aggregate of 50,000 shares vested immediately.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On May 6, 2013, we issued a 10-year stock option to a consultant for the purchase of an aggregate of 96,068 shares with an exercise price of $2.96.&amp;#160;&amp;#160;The shares available under the stock options vest monthly over a 12-month period.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On May 2, 2013, the Compensation Committee of the Board recommended the granting of stock options to our directors.&amp;#160;&amp;#160;The Board approved the recommendation and we issued 10-year stock options for the purchase of an aggregate of 575,000 shares of our common stock with an exercise price of $2.80, as follows: (i) a stock option for the purchase of 225,000 shares of our common stock to the Chairman of the Board; (ii) a stock option for the purchase of 75,000 shares of our common stock to the chair of each committee of the board; and (ii) an Option for the purchase of 50,000 shares of our common stock to each of the remaining directors.&amp;#160;&amp;#160;All of these stock options vest on December 31, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On May 8, 2013, Robert Finizio, our Chief Executive Officer, forfeited his contractual right to receive 600,000 shares upon exercise of a stock option granted in connection with his employment agreement as well as his right to receive any future stock options. Mr. Finizio gave up these rights with the understanding that these stock options would be returned to the pool of stock options available for issuance to attract future employees.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 29, 2013, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 180,109 shares with exercise prices ranging from $1.70 to $2.70.&amp;#160;&amp;#160;An aggregate of 500 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 12,500 shares vest monthly over a 1-year period, 92,109 shares vest monthly over a 13-month period from the date of issuance, and an aggregate of 75,000 shares vest as follows: an aggregate of 31,250 vest immediately and an aggregate of 43,750 vest monthly over the subsequent seven months.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On June 29, 2012, we issued 10-year stock options to employees&lt;font style="display: inline; font-family: Times New Roman"&gt;,&lt;/font&gt; consultants, and a director for the purchase of an aggregate of 250,000 shares with an exercise price of $2.80.&amp;#160;&amp;#160;An aggregate of 7,500 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 115,000 shares vest over a 2-year period on the anniversary of issuance, 2,500 shares vest over a 1-year period on the anniversary of issuance&lt;font style="display: inline; font-family: Times New Roman"&gt;,&lt;/font&gt; 75,000 shares vest monthly from December 31, 2012, and 50,000 vest immediately&lt;font style="display: inline; font-family: Times New Roman"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On April 16, 2012, the Board approved the issuance of 10-year stock options for our directors for the purchase of: (i) an aggregate of 350,000 shares (50,000 shares each) to our directors for services to be rendered during calendar year 2012 and (ii) an aggregate of 75,000 shares (25,000 shares each) to the chairs of the Audit, Compensation and Nominating and Corporate Governance Committees for services to be rendered during calendar year 2012.&amp;#160;&amp;#160;The stock options have an exercise price of $2.55 per share vested in full on December 31, 2012.&amp;#160;&amp;#160;In addition, Dr. Brian Bernick, a director and employee, was issued a stock option for 150,000 shares for services rendered as an employee, having an exercise price of $2.55, which vested in full on April 16, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 30, 2012, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 480,000 shares with an exercise price of $2.40.&amp;#160;&amp;#160;An aggregate of 405,000 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 60,000 shares vest over a 2-year period on the anniversary of issuance, and 15,000 shares vest monthly over a 12-month period from the date of issuance.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On March 30, 2012, the Board approved a cashless exercise provision for use by holders of stock options.&amp;#160;&amp;#160;Also on March 30, 2012, an individual exercised his option to purchase 245,485 shares of our common stock. The aggregate purchase price of approximately $60,000 was paid pursuant to a cashless exercise provision wherein the individual surrendered his right to receive 25,000 shares thereunder.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;On February 27, 2012, we issued stock options to our officers and directors for the purchase of an aggregate of 600,000 shares with an exercise price of $2.20 per share.&amp;#160;&amp;#160;The stock options vested in full on February 27, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;In January 2012, certain individuals exercised their stock options to purchase an aggregate of 1,630,022 shares of our common stock for an aggregate purchase price of $166,000.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;A summary of activity under the LTIP and 2012 SOP and related information follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Number of&lt;br /&gt;&#13;Shares&lt;br /&gt;&#13;Under&lt;br /&gt;&#13;Company&lt;br /&gt;&#13;Option&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Average&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Life in Years&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Aggregate&lt;br /&gt;&#13;Intrinsic&lt;br /&gt;&#13;Value&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at December 31, 2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;13,733,488&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.16&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.7&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,804,117&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,583,677&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.79&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;9.9&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;365,845&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(61,372&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expired&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(600,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at June 30, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,655,793&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.08&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.8&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,038,328&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vested and Exercisable at June 30, 2013&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;9,623,443&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.60&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.5&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;23,208,051&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The weighted-average issue date fair value of stock options issued during the six months ended June 30, 2013 was $1.01.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;At June 30, 2013, we had stock options outstanding with exercise prices ranging from $0.10 to $3.40 per share.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Share-based compensation expense for stock options recognized in our results for the six months ended June 30, 2013 and 2012 ($1,161,770 and $510,987, respectively) is based on awards vested and was estimated without forfeitures.&amp;#160;&amp;#160;ASC 718-10, requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;At June 30, 2013, total unrecognized estimated compensation expense related to non-vested stock options issued prior to that date was approximately $3,695,420 which is expected to be recognized over a weighted-average period of 1.49 years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;A summary of our warrant activity and related information for 2013 follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Number of&lt;br /&gt;&#13;Shares&lt;br /&gt;&#13;Under Company Warrants&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Average&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Life in Years&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Intrinsic &lt;br /&gt;&#13;Value&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at December 31, 2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;12,193,499&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.63&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;17,971,994&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2,100,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.72&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.3&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;867,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expired&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-left: 0pt; margin-left: 9pt"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at June 30, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,293,499&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.79&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;17,985,449&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vested and Exercisable at &lt;/font&gt;June 30, 2013&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;12,149,559&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.67&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;4.3&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;16,540,175&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The assumptions used in the Black-Scholes Model during the six months ended June 30, 2013 are set forth in the table below.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 60%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Six Months&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Ended&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; width: 16%; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Year Ended December 31, 2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.65-1.42&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.61-2.23&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;33.35-45.76&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;40.77-46.01&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 60%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2013-01-01to2013-06-30">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;A summary of activity under the LTIP and 2012 SOP and related information follows:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Number of&lt;br /&gt;&#13;Shares&lt;br /&gt;&#13;Under&lt;br /&gt;&#13;Company&lt;br /&gt;&#13;Option&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Average&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: center; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Life in Years&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Aggregate&lt;br /&gt;&#13;Intrinsic&lt;br /&gt;&#13;Value&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at December 31, 2012&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;13,733,488&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.16&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.7&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,804,117&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Granted&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1,583,677&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;2.79&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;9.9&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;365,845&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(61,372&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Expired&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;-0-&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; padding-bottom: 2px; text-indent: 0pt; padding-left: 0pt; margin-left: 9pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(600,000&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Balance at June 30, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;14,655,793&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;1.08&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7.8&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,038,328&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&#13;&lt;div style="text-align: left; text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Vested and Exercisable at June 30, 2013&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;9,623,443&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;0.60&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;6.5&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; text-align: left; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right; padding-bottom: 4px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;23,208,051&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">In June 2008, we declared and paid a special dividend of $0.40 per share of common stock to all shareholders of record as of June 10, 2008. This amount reflects moneys remaining unclaimed by certain shareholders.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
